Evidence map›Paper›PMID 39541035›Full record

ArticleInfection2025

LTT-Validity in diagnosis and therapeutical decision making of neuroborreliosis: a prospective dual-centre study.

G Summer, V Fingerle, A Spörl, C Lechner, T A Rupprecht

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

G SummerDepartment of Neurology, HELIOS Klinikum München-West, Steinerweg 5, 81241, München, Germany. Gert.Summer@kbo.de.
V FingerleNational Reference Center for Borrelia, LGL Oberschleissheim, Veterinärstrasse 2, 85764, Oberschleissheim, Germany.
A SpörlDepartment of Neurology, HELIOS Amper-Klinikum Dachau, Krankenhausstrasse 15, 85221, Dachau, Germany.
C LechnerDepartment of Neurology, HELIOS Amper-Klinikum Dachau, Krankenhausstrasse 15, 85221, Dachau, Germany.
T A RupprechtDepartment of Neurology, HELIOS Klinikum München-West, Steinerweg 5, 81241, München, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe key objective of this study was to assess the validity of a commercially available in-house Lymphocyte Transformation Test (LTT) as a diagnostic parameter and indicator of disease activity/therapeutic efficacy in the context of Lyme neuroborreliosis (LNB).

methodsA prospective dual-centre study was conducted from 05/14 - 01/18. With respect to Borrelia-LTT a comparison was made between patients suffering from confirmed acute LNB and patients being affected by inflammatory neurologic diseases, defining the control group: Bell's palsy, viral meningitis, herpes zoster, Guillain-Barré-Syndrome and Encephalomyelitis disseminate. Furthermore, we investigated the LTT within the LNB group at the time of admission and again 12 weeks (+/- one week) later - after appropriate antibiotic treatment.

resultsCases included 15 patients with LNB and 58 participants in the control group. With regard to Borrelia-LTT we calculated a low sensitivity of 40% and a moderate specificity of 91% for LNB. Additionally, LTT-levels three months after adequate antibiotic therapy did not correlate with the therapeutic response of LNB patients.

conclusionsThe present study shows that LTT is neither appropriate for LNB detection nor suitable as a follow-up marker.

Indexed as

Lyme NeuroborreliosisAdultAgedAnti-Bacterial AgentsFemaleHumansMaleMiddle AgedProspective StudiesSensitivity and SpecificityYoung AdultAnti-Bacterial AgentsBorrelia-LTTDissemination of B. garinii/B. bavariensisLNBLTTNeuroborreliosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.